Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2019 08:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
May 13, 2019 08:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update

Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine Expect to report in...
May 08, 2019 08:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference

CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
April 08, 2019 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...
March 31, 2019 15:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting

Post-Vaccine Immune and Pathologic Markers Associated with Durable Clinical Benefit in Metastatic Melanoma Patient Cohort Top-line Results, Including 52-Week Clinical Outcomes, from Full NT-001 Trial...
March 11, 2019 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported...
March 04, 2019 08:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
February 27, 2019 19:25 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics to Present at the American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced...
February 21, 2019 08:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics to Present at 8th Annual Leerink Partners Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
January 03, 2019 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Provides Business Update and Outlook for 2019

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today provided a...